Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
Journal of the American College of Cardiology · 2024-04 · 83 (16) · 1568-1578
DOI: 10.1016/j.jacc.2024.01.040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the American College of Cardiology, 2024-04. Verfasst von Veraprapas Kittipibul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. E…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Heart Failure, Hypoglycemic Agents. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to reduce adverse cardiovascular events in patients with type 2 diabetes mellitus, all-cause mortality, and heart failure hospitalization in patients with heart failure, as well as adverse renal outcomes. However, concerns regarding the heightened risk of genitourinary (GU) infections, particularly urinary tract infections, remain a significant barrier to their wider adoption. Addressing these misconceptions using existing evidence is needed to ensure proper risk-benefit assessment and optimal utilization of this efficacious therapy. This review aims to provide a balanced perspective on the evidence-based cardiovascular and renal benefits of SGLT2is and the associated risk of GU infections. We also summarize and propose clinical practice considerations for SGLT2i-associated GU infections focusing on patients with cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: https://twitter.com/vkittipibul.
- Department of Pharmacy Practice, Lipscomb University College of Pharmacy, Nashville, Tennessee, USA; Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennesse…
- Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: robert.mentz@duke.edu.
Zitieren
APA
Kittipibul, V., Cox, Z. L., Chesdachai, S., Fiuzat, M., Lindenfeld, J., & Mentz, R. J. (2024). Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors. Journal of the American College of Cardiology, 83(16), 1568-1578. https://doi.org/10.1016/j.jacc.2024.01.040
Vancouver
Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz RJ. Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors. Journal of the American College of Cardiology. 2024;83(16):1568-1578. doi:10.1016/j.jacc.2024.01.040
BibTeX
@article{Kittipibul2024,
author = {Kittipibul, Veraprapas and Cox, Zachary L and Chesdachai, Supavit and Fiuzat, Mona and Lindenfeld, JoAnn and Mentz, Robert J},
title = {Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors},
journal = {Journal of the American College of Cardiology},
year = {2024},
volume = {83},
number = {16},
pages = {1568--1578},
doi = {10.1016/j.jacc.2024.01.040}
}
EUVIMED